Research priorities in advanced heart failure: James Lind alliance priority setting partnership. by Taylor, Clare J et al.
Open access 
  1Taylor CJ, et al. Open Heart 2020;7:e001258. doi:10.1136/openhrt-2020-001258
To cite: Taylor CJ, Huntley AL, 
Burden J, et al. Research 
priorities in advanced heart 
failure: James Lind alliance 
priority setting partnership. 
Open Heart 2020;7:e001258. 
doi:10.1136/
openhrt-2020-001258
Received 3 February 2020
Revised 3 April 2020
Accepted 21 April 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Rachel Johnson;  epraj@ 
bristol. ac. uk
Research priorities in advanced heart 
failure: James Lind alliance priority 
setting partnership
Clare J Taylor  ,1 Alyson L Huntley,2 John Burden,3 Amy Gadoud,4 
Toto Gronlund,5 Nicholas Robert Jones  ,6 Eleanor Wicks,7 Sara McKelvie,8 
Kit Byatt,9 Richard Lehman,10 Anna King,11 Bev Mumford,12 Gene Feder,2 
Jonathan Mant,13 Richard Hobbs,14 Rachel Johnson  15
Heart failure and cardiomyopathies
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
Key messages
What is already known about this subject?
 ► Research priorities are typically set by funders and 
researchers, yet it is known that involving stake-
holders, including patients and clinicians, can pro-
duce research that is more credible and relevant to 
stakeholders.
What does this study add?
 ► In this study, research priorities for advanced heart 
failure (HF) were developed in collaboration with 
patients, carers and clinicians using an extensively 
validated method. The resultant top 10 research pri-
orities for advanced HF can be used by researchers 
and funders to influence the HF research agenda.
How might this impact on clinical practice?
 ► Through influencing the HF research agenda, this 
has the potential to lead to credible, relevant re-
search that focuses on the questions important to 
patients, carers and clinicians.
AbstrAct
Objective To determine research priorities in advanced 
heart failure (HF) for patients, carers and healthcare 
professionals.
Methods Priority setting partnership using the 
systematic James Lind Alliance method for ranking 
and setting research priorities. An initial open survey of 
patients, carers and healthcare professionals identified 
respondents’ questions, which were categorised to 
produce a list of summary research questions; questions 
already answered in existing literature were removed. 
In a second survey of patients, carers and healthcare 
professionals, respondents ranked the summary research 
questions in order of priority. The top 25 unanswered 
research priorities were then considered at a face- to- face 
workshop using nominal group technique to agree on a 
‘top 10’.
Results 192 respondents submitted 489 responses 
each containing one or more research uncertainty. Out- 
of- scope questions (35) were removed, and collating the 
responses produced 80 summary questions. Questions 
already answered in the literature (15) were removed. 
In the second survey, 65 questions were ranked by 128 
respondents. The top 10 priorities were developed at a 
consensus meeting of stakeholders and included a focus 
on quality of life, psychological support, the impact on 
carers, role of the charity sector and managing prognostic 
uncertainty. Ranked priorities by physicians and patients 
were remarkably divergent.
Conclusions Engaging stakeholders in setting research 
priorities led to a novel set of research questions that 
might not have otherwise been considered. These priorities 
can be used by researchers and funders to direct future 
research towards the areas which matter most to people 
living with advanced HF.
IntROduCtIOn
Heart failure (HF) is a common condition 
affecting one to two in every hundred adults 
in the UK1 and one in six people aged over 
85 years.2 People with HF can experience 
symptoms of breathlessness, tiredness and leg 
swelling; have a reduced quality of life; and 
may require hospital admission.3 Treatment 
of HF includes medications, exercise- based 
rehabilitation, device therapies and, in a 
small number of cases, transplantation.4 5
There are many areas of healthcare, 
including the management of people with 
advanced HF, where the right treatment 
approach is sometimes unclear.6 In advanced 
HF, this may reflect the fact there is signifi-
cant heterogeneity in important disease char-
acteristics such as aetiology, treatment and 
disease course. Advanced HF guidelines and 
policy documents often focus on hospital 
inpatients.7 The majority of people with 
HF are community- dwelling older people 
with multiple comorbidities who are under- 
represented in research studies.8 9
Traditionally, researchers formulate 
the research questions they feel are most 
important and apply to funders to undertake 
work which will provide an answer. In the 
field of advanced HF, research has focused 
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on younger, often male patients. In recent years, national 
funding bodies have advocated for more involvement of 
patients in setting the research agenda, notably through 
National Instute for Health Research (NIHR) INVOLVE, 
a government- funded programme to support active 
public involvement in research. The James Lind Alli-
ance (JLA), a non- profit- making initiative partly funded 
by the National Institute for Health Research (NIHR), is 
committed to ensuring those most affected by a condition 
are involved in prioritising research by bringing together 
patients with the condition, their carers and clinicians 
to determine the key priorities for future research.10 11 
The JLA’s method for involving stakeholders, including 
patients and clinicians, in setting research priorities has 
been extensively tested and validated across a wide range 
of conditions accessible online (http://www. jla. nihr. ac. 
uk/ priority- setting- partnerships) and is recognised as the 
best currently available method for undertaking this.
The perceived research priorities for people living with 
advanced HF in a community setting are unknown. Our 
objective, therefore, was to work with patients, carers 
and clinicians to establish, for the first time, the research 
priorities for people with advanced HF using the system-
atic JLA priority setting method.
MetHOds
Priority setting involves gathering data from key stake-
holders to arrive at a prioritised set of questions which 
can be answered through future research projects. This 
differs from standard research studies as the aim was to 
find research questions rather than answers. The most 
robust and well- tested method for priority setting with 
healthcare stakeholders has been developed by the JLA, 
and the full methodology is described in their published 
guidance.11 The process for the advanced HF priority 
setting partnership (PSP) is summarised in figure 1.
setting up the PsP
The PSP was established in April 2017 as a collaboration 
between clinicians involved in managing people with 
advanced HF, led by two general practitioners (GPs) with 
expertise in HF management and research (CJT and RJ). 
Data analysis was carried out by an experienced informa-
tion specialist (ALH), a senior evidence synthesis scien-
tist with significant experience of working on applied 
health research studies including those focused on HF. 
The NIHR Evaluation, Trials and Studies Coordinating 
Centre allocated a JLA adviser to help set up the PSP and 
provide support throughout the process (TG).
A steering group oversaw the PSP, meeting eight times 
during the process. The steering group comprised 18 
members (6 men and 12 women), including 4 patients, 
2 carers, 6 healthcare professionals (HF nurse specialist, 
palliative care nurse, cardiologist, geriatrician, palliative 
medicine consultant and GP), the core PSP team (CJT, 
RJ, ALH and TG) and one observer. Members had links 
to wider partner networks, including charities, patient 
groups and professional organisations.
scope
The scope of this PSP was the management of adults (age 
18 years and over) with advanced HF in the community, 
including physical health (symptoms and treatments), 
emotional well- being and support services, but excluding 
HF diagnosis. The steering group highlighted the chal-
lenge of identifying people with advanced HF in this 
context: for stakeholders to identify the PSP as relevant 
to them, a definition of advanced HF that would be 
meaningful to patients and carers was required. There 
is no universally agreed definition for advanced HF 
either within the clinical community or among patient 
and carer groups. The European Society for Cardiology 
definition includes investigation findings, but patients 
themselves are unlikely to know detailed echocardiogram 
results.12 For this PSP, we defined a patient with advanced 
HF in the community as ‘a person with a known diagnosis 
of HF who has symptoms, such as breathlessness, which 
impact on their quality of life, and may require them to 
take multiple medications and be admitted to hospital 
but who are not currently an inpatient.’
Patient and public involvement and engagement (PPIe)
The JLA process aims to equally involve people with lived 
experience of HF and their healthcare professionals 
in setting priorities for research. However, the steering 
group recognised that people with advanced HF in the 
community may be a particularly hard- to- reach group, so 
a separate PPIE group (seven members) was established to 
work alongside the steering group and provide additional 
advice from the perspective of patients with advanced HF. 
The PPIE group provided input into the development of 
both the initial and interim prioritisation surveys. Specifi-
cally, the group provided feedback on the wording of the 
survey (readability and ease of understanding), and the 
usability of the online and paper versions.
Identifying unanswered questions
The aim of the initial survey was to collect raw, unan-
swered questions from patients, clinicians and carers with 
experience of advanced HF. The survey was designed and 
piloted by the steering group, together with the PPIE 
group. In designing the survey questions, the steering 
group considered question formats used in previous PSPs. 
Prompts, including example answers, were included at 
the recommendation of patients and carers in the PPIE 
group/steering group to help respondents understand 
how to answer the questions. The survey was open from 
June to September 2018 and was available in online, 
paper and easy- read versions. Respondents were asked 
three open questions about the physical and emotional 
impacts of advanced HF, and the treatment, support or 
help provided for people with the condition (figure 2).
To encourage survey completion, data collection was 
kept to a minimum and was limited to factors that were 
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Figure 1 James Lind Alliance process overview.
likely to influence respondents’ suggested questions. 
Patients were asked basic demographic details (age, sex 
and ethnicity), and healthcare professionals were asked 
to define their professional group in order to check 
whether we were successful in sampling across these 
groups.
The JLA process requires surveys to be widely distributed 
through multiple channels and open access to patients 
and the public. The overall sample size or ‘denominator’ 
for the survey is therefore not known. Steering group 
members raised awareness of the survey through their 
respective networks, for example, charities, including 
Pumping Marvellous, linked to the survey through their 
social media, and clinicians handed out surveys in prac-
tices and outpatient cardiology clinics. Social media was 
used to promote the survey widely, and relevant charities, 
including Carers UK and the British Heart Foundation, 
were contacted.
Refining questions
Survey responses (489 responses to individual survey ques-
tions from 192 respondents) were assembled, categorised 
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Figure 2 Initial survey questions: Main question, Prompts.
and refined by the steering group to form summary 
questions. This was a collaborative process: all submitted 
questions were considered, and questions with a similar 
theme (eg, questions about how to use diuretics) were 
iteratively grouped into categories (figure 1). Working 
in groups that included a mix of healthcare profes-
sional and patient or carer, questions within categories 
were discussed, and similar or duplicate questions were 
combined where appropriate, and questions deemed out 
of scope were referred back to the wider steering group to 
consider whether they should be removed. This process 
resulted in the list of summary questions for the second 
(prioritisation) survey. The JLA adviser ensured contribu-
tion of all steering group members to this process. System-
atic reviews and guidelines were identified and checked 
by the information specialist and PPIE lead, referring to 
clinical members of the steering group when needed, to 
see to what extent these refined questions had, or had 
not, been answered by previous research. Some questions 
could be answered with existing information and were 
removed from the prioritisation process at this stage.
Interim prioritisation
A second ‘prioritisation’ survey was distributed via 
the same multiple channels as the first survey and was 
intended to reach an equally wide audience. A link to the 
second survey was posted on the PSP website. Respond-
ents to the first survey who had provided contact details 
were invited to complete this second survey. Steering 
group members also distributed the survey through their 
stakeholder networks.
The aim of the interim prioritisation stage was to 
proceed from the longer list of questions generated 
from the initial survey to a shorter list, which could be 
taken to the final workshop. Respondents were asked to 
choose their ‘top 10’ from a shortlist of summary ques-
tions and provide basic demographic details. We used 
the online platform Optimal Workshop Card Sort for the 
survey. Using this platform, we presented questions in a 
randomly generated order to avoid respondents prefer-
encing questions at the top of the list; respondents were 
asked to choose their top 10 questions. Paper copies of 
the survey were also available. The second survey was 
open from January 2019 to February 2019. Responses 
to the second survey were organised by the number of 
respondents choosing each question and by professional 
group. In accordance with the PSP process, the highest- 
ranking questions were included in a shortlist of 25 ques-
tions to be discussed at the final workshop.
Final workshop
The final prioritisation stage was conducted in a face- 
to- face meeting attended by a total of 30 participants, 
including patients, carers and healthcare professionals, 
most of whom had not been involved in the PSP process. 
The workshop was observed by members of the steering 
group, researchers and the British Heart Foundation, 
which funds cardiovascular research. Three experi-
enced JLA advisers facilitated group discussions to 
build consensus towards the final top 10 research prior-
ities using the nominal group technique.13 Workshop 
attendees worked in three groups, including a mix of 
patients, carers and healthcare professionals. Facilitated 
by the JLA advisers, the groups discussed the shortlist of 
questions and proposed a priority order, before groups 
were alternated and the process repeated. The proposed 
ordering of the three groups was collated and presented 
to the whole group, and in a final facilitated discussion, 
the top 10 priorities were agreed.
Results
Initial survey
A total of 192 respondents completed the initial survey. 
These included 74 patients, 17 carers, 92 health profes-
sionals and 9 others. Only patients were asked for demo-
graphic details (table 1).
data analysis
A total of 489 responses which contained one or more 
research questions were submitted in response to the 
survey questions on physical health, emotional well- being 
and treatment. Thirty- five questions were removed as they 
were out of scope (eg, questions related to diagnosis), 
and the remaining 454 were ordered into 10 categories 
(figure 1).
The research questions were combined, with duplicates 
removed, to form 80 summary questions. These were 
checked against existing literature and 15 answered ques-
tions were removed. The remaining 65 summary ques-
tions were grouped into three key themes: living with 
advanced HF (22), how advanced HF is managed by the 
health service (23) and talking with health professionals 
about what the future holds (20). These were included 
in the second survey with the questions presented in a 
random order (appendix 1).
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Table 1 Role of participants and demographic details for 
patients with heart failure in the initial and interim surveys
Initial survey 
(n)
Interim 
survey (n)
Role
  Patient 74 17
  Carer 17 15
  Healthcare professional 92 96
  Other 9 0
Age (years) (patients only)
  <40 6 2
  41–50 14 2
  51–60 18 4
  61–70 19 3
  71–80 12 2
  >80 5 0
Sex (patients only)
  Male 34 4
  Female 39 10
  Not stated 1 3
Ethnicity (patients only)
  White British 69 16
  Black African 1 0
  Mixed 2 0
  Not stated 2 1
Interim prioritisation
Respondents were asked to pick their top 10 questions 
from a list of 65 summary questions. A total of 128 
respondents completed the survey online using Card 
Sort, with no paper surveys being returned: 17 patients, 
15 carers and 96 healthcare professionals. The top ranked 
priorities in the interim survey were different between 
patients/carers and healthcare professionals: of the top 
13 priorities chosen by each group (patients/carers and 
healthcare professionals), only one question was chosen 
by both groups (figure 3). To ensure a balance in the 
shortlist for the final workshop, the top 13 priorities for 
the patient/carers and the top 13 for the healthcare 
professional groups (ie, including one priority which 
both groups ranked highly) were included on the short-
list.
Final workshop
The final workshop included 26 participants: 5 patients, 
3 carers, 6 GPs, 2 HF nurse specialists, a cardiologist, 
a geriatrician, 3 GP cardiologists, a physiotherapist, a 
cardiology research nurse, 2 charity representatives and 
a patient and public involvement facilitator. The top 10 
research priorities determined at the final workshop are 
shown in table 2. The top 10 priorities included questions 
that had been shortlisted because they were in the top 13 
for patients (5), healthcare professionals (4) or both (1).
dIsCussIOn
summary
This is the first attempt to formally identify future research 
priorities in advanced HF. We used the JLA method to 
engage patients, carers and healthcare professionals. The 
initial survey yielded 489 research questions which were 
sorted, categorised and checked against existing liter-
ature to generate a final list of 65 summary questions. 
These were considered in a second prioritisation survey 
to generate a list of 25 questions, which were taken to a 
final workshop where the top 10 list of research priori-
ties was generated through consensus. Interestingly, the 
priorities for patients and carers differed completely 
from healthcare professionals in the interim survey. For 
patients and carers, quality of life and managing uncer-
tainty were most important, whereas healthcare profes-
sionals’ priorities comprised ‘difficult conversations’ and 
drug treatment. However, at the final prioritisation stage, 
patients, carers and healthcare professionals aligned in 
the importance of patient empowerment, end- of- life 
care, psychological support and the vital role of carers.
strengths and limitations
This study has several strengths. We used an established 
method, one which has been used by government and 
charities to prioritise future funding in health services 
research,7 to determine research priorities of patients, 
carers and healthcare professionals affected by advanced 
HF. Our committed steering group was involved 
throughout, including in survey design, review and 
analysis of the data, and survey dissemination. Surveys 
were developed with patient and carer input (including 
those over 80 years old) and were designed to make data 
collection straightforward; an easy- read version of the 
survey was developed and made available. We attempted 
to access black and minority ethnic groups through 
our stakeholder group contacts. The initial survey was 
disseminated widely in a range of settings and had a 
good response across a range of patient age groups. The 
meaning of advanced HF is different between patients, 
carers and professional groups; our definition was 
designed to allow a prioritisation exercise to take place 
in which patients and carers could participate. The prior-
ities for patients and carers were different from those of 
healthcare practitioners, which highlight the importance 
of conducting this type of priority setting exercise.
We acknowledge several limitations. We did not collect 
patient- identifying information; therefore, we are able to 
describe the survey respondents only in limited terms, 
and are unable to draw comparisons between the first 
and second survey respondents. We did not collect data 
on deprivation or educational level, but more articu-
late and engaged people are more likely to complete 
surveys, which may have introduced a bias in terms of 
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Figure 3 Twenty- five shortlisted questions discussed at the final workshop. COPD, chronic obstructive pulmonary disease; 
ICD, implantable cardioverter–defibrillator.
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Table 2 Top 10 research priorities from the final workshop
Research priority
Group (patients, carers or healthcare 
professionals) whose survey responses were 
incorporated into this research question
1. Which treatments have the biggest impact on the quality of life of people with 
advanced HF?
Patients
2. What amount and type of exercise is safe and effective for people with advanced 
HF?
Patients and healthcare professionals
3. What is the most empowering and effective education and self- management 
advice for people with advanced HF and their carers? (eg, dealing with fatigue)
Patients, carers and healthcare professionals
4. How can the work of HF charities be better integrated with NHS services to 
optimise the care of people with advanced HF?
Patients
5. Which approaches, in addition to standard therapies, are effective in supporting 
breathlessness in people with advanced HF?
Healthcare professionals
6. How do we break down barriers for patients with advanced HF, carers and health 
professionals to enable talking about end of life care?
Patients, carers and healthcare professionals
7. What are the benefits of asking a person with advanced HF ‘what is important to 
you’?
Healthcare professionals
8. What is the most effective way to use diuretics in advanced HF, with respect to 
fluid overload, kidney function, survival and quality of life?
Healthcare professionals
9. How can patients with advanced HF and professionals be helped to 
communicate about symptoms that are difficult to express such as anxiety and 
low mood?
Patients and healthcare professionals
10. What support would be most effective for carers of people with advanced HF? 
(eg, support groups)
Patients and healthcare professionals
HF, heart failure.
socioeconomic gradient.14 The second survey had a lower 
response rate.
We found it challenging to engage with the over 80- year 
age group despite efforts to access older adults through 
steering group member networks, and our success at 
reaching black and minority ethnic groups was limited.
Comparison with existing literature
Previous PSPs have covered a variety of healthcare topics, 
including diabetes mellitus, inflammatory bowel disease, 
renal transplantation, fragility fractures and congenital 
heart disease.15–19 Each PSP has used existing networks to 
engage relevant groups of patients, carers and healthcare 
professionals. Some diseases, such as diabetes mellitus, 
have large, often well- engaged patient groups, so the 
number of respondents was higher.15 HF is a difficult, 
often frightening, term which is not well recognised by 
the general public.20 Even people with a diagnosis of HF 
may not always know they have the condition. HF also 
rarely occurs in isolation, with over two- thirds of people 
with HF living with three or more comorbidities.1 This 
may mean HF is not their main source of concern or 
focus of healthcare and that people may be uncertain 
which of their symptoms are attributable to HF and there-
fore a research uncertainty in this area.
The JLA process yielded a different set of priorities 
for patients/carers and healthcare professionals at 
the interim survey stage. Other PSPs, such as the head 
and neck cancer PSP, had similar results.21 Patients and 
carers wanted to understand more about their condi-
tion in the advanced stages of disease, feel empowered 
to safely self- manage and be able to have conversations 
with healthcare professionals about their future. Health-
care professionals prioritised a more medical model, with 
questions around drug management and the provision 
of advanced care planning documentation. They also felt 
research around end- of- life conversations was needed. 
This supports previous qualitative research which found 
patients did want to have conversations about prognosis 
and end- of- life care, but clinicians often feared causing 
premature alarm and destroying hope and so waited for 
patients to give cues about wanting these discussions.22 23
Policy and future research
In this study, we have identified research areas most 
important to patients and those supporting their care. 
The priorities identified reflect a change in focus to that 
of major HF research funders, whose research often 
focuses on understanding biological mechanisms and 
treatments to address these and on outcomes including 
disease measures and health service use.24 25 Guidelines 
for chronic HF management reflect the available evidence 
described previously and do not directly address many of 
the priorities identified in this JLA process.4 Addressing 
the questions identified within this top 10 requires the 
use of multiple research methods, including qualitative 
approaches in contrast to the traditional randomised 
clinical trial approach. This highlights the value of asking 
Open Heart
8 Taylor CJ, et al. Open Heart 2020;7:e001258. doi:10.1136/openhrt-2020-001258
patients, carers and frontline healthcare professionals for 
their ideas on research and what they feel is most impor-
tant for people living with the condition. Research prior-
itisation in the UK and globally relies on governments 
and research funders to set the agenda. This can be influ-
enced by charities and lobby groups, and incorporated in 
guideline and policy documents.4 5 22 23 Governments and 
funders should recognise the role of a formal prioritisa-
tion processes, such as the JLA method, in determining 
funding priorities. As recently encouraged by NIHR lead-
ership, this report should be used to inform researchers 
applying for funding to take forward these research 
priorities. For advanced HF, a focus on quality of life, 
managing uncertainty and the role of carers and charities 
should be included in the future research agenda.
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